** Shares of drug developer Milestone Pharmaceuticals MIST.O fall 8% to 73 cents, extending decline to third day
** Brokerage TD Cowen downgrades MIST to "hold" from "buy", removes PT
** Cites etripamil's regulatory and commercial timing uncertainty
** "The lack of clarity on regulatory timelines puts additional strain on the company's limited capital," says brokerage
** MIST shares fell ~61% on Friday after the U.S. FDA declined to approve its nasal spray, Cardamyst, to treat a type of heart condition
** Including session moves, MIST stock down ~69% YTD compared to ~5% decline in the S&P 500 index .SPX
(Reporting by Ateev Bhandari in Bengaluru)
((Ateev.Bhandari@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。